How does breast cancer mortality compare with that of other cancers and selected cardiovascular diseases at different ages in U.S. women? [2] Risk factors that attenuate the female coronary disease advantage [3] Reproductive hormones and the menopause transition [4] Coronary heart disease and hormone replacement therapy after the menopause [5] Christiansen c. Long-term prevention with hormone-replacement therapy after the menopause: Which women should be targeted? [6] Protective effects of estrogen on the cardiovascular system [7] Hormone replacement therapy of menopause, heart and blood vessels [8] Familial lipoprotein disorders and premature coronary artery disease [9] Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol [10] Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosis, CHS Collaborative Research Group, Cardiovascular Health Study [11] Targeting low HDLcholesterol to decrease residual cardiovascular risk in the managed care setting [12] Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events [13] Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women [14] The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys [15] Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women [16] Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patientsAims Cardiovascular diseases are one of the most important complications in menopausal period. The complications are one of the major causes of death in women. Clearance of chylomicrons increases with hormone replacement therapy (HRT) that is a protective effect of estrogen against cardiovascular diseases. The objective of this study was to evaluate the postmenopausal hormone therapy effects on atherogenic factors and chylomicron levels.Materials & Methods This study was conducted on all women with complications of menopause or women's problems who referred to Sarem medical center during 6 month from 1999 to 2000. The lipid and lipoprotein factors were measured before HRT therapy and six months after the treatment. Data were collected by a questionnaire including demographics, blood pressure, weight, height, and other clinical data. The total cholesterol, triglyceride, HDL, LDL, risk factor (RF), atherogenic factor (AI) and hormonal tests were evaluated before and after treatment. The data were analyzed by Wilcoxon and t tests. Findings There were significant relationships between HRT with the increase of HDLC, and reduction of LDLC, RF and AI (p<0.05). However, there were no significant relationships between HRT and triglyceride and cholesterol serum levels. Conclusion Hormone therapy increases HDLC and decreases LDLC, RF, and AI, and ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.